Update on HIV in Western Europe
Nakagawa, Fumiyo; Phillips, Andrew N; Lundgren, Jens

Published in:
Current HIV - AIDS Reports

DOI:
10.1007/s11904-014-0198-8

Publication date:
2014

Document Version
Publisher's PDF, also known as Version of record

Citation for published version (APA):
Nakagawa, F., Phillips, A. N., & Lundgren, J. D. (2014). Update on HIV in Western Europe. DOI: 10.1007/s11904-014-0198-8
Update on HIV in Western Europe

Fumiyo Nakagawa · Andrew N. Phillips · Jens D. Lundgren

Published online: 22 March 2014 © The Author(s) 2014. This article is published with open access at Springerlink.com

Abstract HIV infection in Western Europe is mainly concentrated among men who have sex with men, heterosexuals who acquired HIV from sub-Saharan African countries, and in people who inject drugs. The rate of newly diagnosed cases of HIV has remained roughly stable since 2004 whereas the number of people living with HIV has slowly increased due to new infections and the success of antiretroviral therapy in prolonging life. An ageing population is gradually emerging that will require additional care. There are large differences across countries in HIV testing rates, proportions of people who present to care with low CD4+ cell counts, accessibility to treatment and care, and rates of retention once in care. Improved collection of HIV surveillance data will benefit countries and help to understand their epidemic better. However, social inequalities experienced by people with HIV still remain in some regions and urgently need to be addressed.

Keywords HIV infection · HIV/AIDS · HIV · Western Europe · Global epidemic · Europe · HIV testing rates · Antiretroviral therapy · State of the epidemic

Introduction

HIV infection has had a large impact in Western European countries over the last 35 years of the pandemic and continues to affect growing numbers of people. In this review, we summarise key issues and highlight recent articles surrounding the evolution of the HIV epidemic in Western Europe. We focus on the 23 countries found in the West region of the World Health Organisation (WHO) European region (Table 1).

Current State of the Epidemic

The Joint United Nations Programme on HIV/AIDS (UNAIDS) estimates that 860,000 [800,000–930,000] adults were living with HIV in this area of Europe by the end of 2012 [1]. This figure is estimated to have been 360,000 [320,000–400,000] and 570,000 [520,000–600,000] in 1990 and 2000 respectively [1]. UNAIDS estimates are calculated using the Spectrum/Estimation and Projection Package (EPP) software and require country-specific HIV surveillance and survey data [2, 3]. The increasing trend in number of people living with HIV in Europe is a combined result of continued new infections and people living longer because of the success of antiretroviral therapy (ART) [4]. Mortality rates in people with HIV have declined substantially, with most countries in Western Europe having observed at least a 50 % decline from the peak in the mid-1990s to present [5••]. Disability-adjusted life years (DALYs) are used to measure the overall burden of a disease and can be interpreted as the years of potential life lost, due to premature death, disability or ill-health. DALYs are calculated by summing the years of life lost due to premature mortality and the years lived with disability. Estimates of DALYs for HIV in Western Europe are significantly lower than any other region in the world, in which no country has greater than 60,000 DALYs attributed to HIV (Table 1).
compares with 11,915,000 DALYs in South Africa where HIV is the leading cause of DALYs, and 588,000 DALYs in the United States [5].

In 2012, there were 27,315 newly diagnosed cases of HIV reported in Western Europe [6]. This translates to a rate of 6.6 newly diagnosed cases of HIV reported per 100,000 population. The rates of newly diagnosed cases have remained stable since 2004 (all countries except Monaco have been reporting data since 2004 to the European Centre for Disease Prevention and Control, ECDC), with an average of between 6.5 and 7.8 cases per 100,000 each year. Trends over time in this rate however, differ substantially by mode of HIV transmission (Fig. 1) among countries where this has been routinely collected since 2004.

Countries in Western Europe largely have concentrated HIV epidemics, that is, epidemics which are concentrated among sub-populations, particularly men who have sex with men (MSM) and people who inject drugs (PWID). The number of reported HIV diagnoses per year has declined in most transmission groups, including among PWID, cases of mother-to-child transmission (MTCT) and heterosexually acquired cases. Worryingly, a slow but steady increase has been observed in cases among MSM, largely due to rises in number of reported cases in the UK, Belgium, Germany and Israel. The UK contributes around a third of all reported diagnoses among MSM.

The reported data suggest that the HIV epidemic in Western Europe is being fuelled mainly by sexual transmission. In 2012, the distribution of new reported HIV diagnoses by mode of transmission was as follows: sex between men 41.7 %, heterosexual sex 35.3 %, injecting drug use 5.1 %, MTCT 0.7 % and unknown 17.2 %. For every one female diagnosed with HIV, there were 3.1 males diagnosed. Among reported cases in 2012, 9.8 % were in people aged 15 to 24 years old and 16.7 % of cases in people over the age of 50 [6].

Table 1 Data from 2012 on the HIV epidemic in Western Europe: number of HIV diagnoses, estimated number of people living with HIV and disability-adjusted life years (DALYs) attributable to HIV/AIDS

| Country | Country population as of 2013 (per million) | Number of HIV diagnoses in 2012 | UNAIDS estimate1 of the number of people living with HIV in 2012 [1] | Number of DALYs2 attributable to HIV/AIDS (in thousands) |
|---------|---------------------------------------------|-------------------------------|----------------------------------------|-----------------------------------------------|
| Andorra | 0.09 | 2 | 2.4 | — | 0.0 |
| Austria | 8.2 | 306 | 3.6 | 13,000 | 25,000 | 3.8 |
| Belgium | 10.4 | 1227 | 11.1 | 16,000 | 26,000 | 5.3 |
| Denmark | 5.6 | 201 | 3.6 | 5500 | 7500 | 2.8 |
| Finland | 5.3 | 156 | 2.9 | 2600 | 3600 | 1.2 |
| France | 66.0 | 4066 | 6.2 | 120,000 | 180,000 | 48.9 |
| Germany | 81.1 | 2593 | 3.6 | 62,000 | 78,000 | 29.2 |
| Greece | 10.8 | 1059 | 9.4 | 9300 | 13,000 | 26.7 |
| Iceland | 0.3 | 219 | 2.2 | <500 | <1000 | 0.4 |
| Ireland | 4.8 | 339 | 7.4 | 6300 | 10,000 | 1.7 |
| Israel | 7.7 | 487 | 6.4 | 6700 | 11,000 | 3.2 |
| Italy | 61.5 | 3898 | 6.4 | 110,000 | 140,000 | 55.3 |
| Luxembourg | 0.5 | 54 | 10.3 | <1000 | 1100 | 0.3 |
| Malta | 0.4 | 30 | 7.2 | <500 | <500 | 0.1 |
| Monaco | 0.03 | 0 | 0 | — | — | — |
| Netherlands | 16.8 | 976 | 5.8 | 20,000 | 34,000 | 5.2 |
| Norway | 4.7 | 242 | 4.9 | 3600 | 6300 | 1.2 |
| Portugal | 10.8 | 721 | 7.0 | 38,000 | 62,000 | 42.8 |
| San Marino | 0.03 | 5 | 15.5 | — | — | — |
| Spain | 47.4 | 3210 | 8.5 | 140,000 | 170,000 | 56.2 |
| Sweden | 9.1 | 363 | 3.8 | 7200 | 13,000 | 1.9 |
| Switzerland | 8.0 | 643 | 8.1 | 16,000 | 27,000 | 6.8 |
| United Kingdom | 63.4 | 6358 | 10.3 | 76,000 | 120,000 | 22.2 |

1) A “best” estimate of the number of people living with HIV in 2012 by country is not given by UNAIDS. 2) DALYs are calculated as the summation of YLLs (years of life lost due to premature mortality) and YLDs (years lived with disability). Disability weights used to calculate YLDs in reference [5] were: 0.339 for HIV disease resulting in mycobacterial infection, 0.051 for HIV pre-AIDS asymptomatic, 0.221 for HIV pre-AIDS symptomatic, 0.053 for AIDS with antiretrovirals and 0.547 for AIDS without antiretrovirals.
Surveillance of the Epidemic

Knowledge and understanding of epidemics, including monitoring of epidemiological trends and patterns is crucial to inform public health interventions and policies. UNAIDS and WHO have recently published new comprehensive HIV surveillance guidelines to reflect the changing situation, notably wider access to antiretroviral therapy (ART) and prevention of mother-to-child transmission (PMTCT) approaches [7]. On the European level, surveillance for HIV infection has been conducted jointly by ECDC and WHO Regional Office for Europe (WHO/E) since 2007 [8] and by EuroHIV previously [9]. Countries are requested to report each year, the number of HIV diagnoses, AIDS diagnoses, CD4 cell + count (CD4 count) at diagnosis and number of HIV tests performed, to the ECDC through The European Surveillance System (TESSy).

Reports on the number of HIV and AIDS diagnoses, known as ‘case reporting’, form the backbone of HIV surveillance in Europe. Most countries in Western Europe now have nationally established HIV/AIDS case reporting systems (Italy reported national-level data for the first time in 2012 and Spain report aggregate regional-level data, for which coverage has been gradually increasing over time). Many countries also conduct prevalence surveys and cross-sectional qualitative surveys on a regular basis to estimate HIV prevalence and indicators of transmission risk behaviours in key subpopulations [10, 11]. Second generation surveillance of HIV includes surveillance of risk behaviour and surveillance of sexually transmitted infections in addition to case reporting [7]. HIV antibody assay-based approaches to estimate whether an infection was acquired recently (4–12 months) are increasingly used to estimate HIV incidence [12, 13•, 14]. In addition, the SPREAD surveillance programme monitors levels of transmitted drug resistance in newly diagnosed treatment-naïve individuals across Europe [15].

Information obtained through surveillance can contribute to producing estimates of the numbers of people living with HIV and equally importantly, the numbers of people infected but not yet diagnosed. Although the quality and quantity of data collected through surveillance by countries in Western Europe have improved over time, there still remain tricky issues over possible under- and delayed-reporting of cases. One modelling study in 2008 estimated that 35 % of HIV-positive individuals were thought to be undiagnosed in the whole of Western Europe [16]. As yet, relatively few countries have carried out any modelling work to estimate the size of the undiagnosed population in their own countries.

HIV Care Cascade

The first stage of the spectrum of engagement in HIV care, otherwise commonly referred to as the ‘HIV care cascade’, is the proportion of people with HIV who are aware of their diagnosis status [17]. The subsequent stages are: proportion linked to HIV care, proportion retained in HIV care, proportion receiving ART, and then the proportion with viral suppression. The care cascade is a useful concept to quantify the success of HIV care services and access to ART. Increasing the proportion of HIV-positive people who are on ART with viral suppression is an important aim for HIV prevention, as those with viral suppression are unlikely to transmit HIV [18, 19]. It is encouraging to see that many countries have started to provide such figures, with many reporting that approximately 60 to 70 % of diagnosed HIV-infected individuals are thought to have an undetectable viral load [20–22].

Testing

A reduction in the proportion of people with HIV who are undiagnosed will be primarily achieved through expansion in
coverage and frequency of HIV testing. Even in Western Europe, where ART is widely and generally freely available to all those diagnosed and in need, HIV testing rates vary substantially from 1.9 (Greece) to 119.5 (San Marino) tests performed per 1000 population (where data are collected and excluding unlinked anonymous testing and testing of blood donations) [6]. As a large proportion of transmissions are thought to originate from individuals who are not yet diagnosed [23, 24], earlier and more frequent testing is paramount to benefit, both on an individual- and population-level. In particular, the HIV in Europe Initiative (www.hiveurope.eu) has been successful in promoting optimal HIV testing and earlier care in Europe [25]. Delineation of persons presenting late for care have identified that many were in contact with the health system several times before being diagnosed and hence increased provided-initiated testing is likely to be helpful. The HIV Indicator Diseases across Europe Study (HIDES) was a result of the HIV in Europe 2007 Conference, with the aim to improve targeted testing for people most likely to be infected with HIV [26]. The study authors found that it would be cost-effective to offer an HIV test to anyone presenting with one of eight indicator conditions (sexually transmitted infection, lymphoma, cervical or anal cancer/dysplasia, herpes zoster, hepatitis B/C, mononucleosis-like illness, unexplained leukocytopenia/thrombocytopenia and seborrheic dermatitis/exanthema) [27•].

Although many European countries already have national guidelines for HIV testing [28], ECDC has also issued an evidence-based guidance for testing programmes to help inform recommendations and scale up testing further [29]. Access to testing however seems to vary widely across healthcare settings in Europe: although most countries offer HIV tests in HIV clinics, sexual health clinics, hospitals and antenatal settings, tests are less available through general practitioners, prisons and tuberculosis services [28]. HIV testing has also been found to be feasible in emergency departments, community-based centres and through use of laboratory-based testing of oral fluid, where each have their own benefits and difficulties in implementation [30–33, 34•]. A systematic review assessing barriers to testing in Europe found that there are barriers concerning patients, healthcare providers and at the level of institutions, which include perceived low-risk, fear, accessibility, as well as lack of financial and human resources [35]. These need to be addressed to ensure earlier diagnosis and wide access to care to prevent excess morbidity and mortality. Nonetheless, there is momentum to normalise HIV testing, by means of routine testing such as wider use of opt-out testing, including use of rapid testing, self-sampling (where the sample is posted for the test to be performed), and self-testing (where the person both takes the sample and performs the test themselves) [36, 37].

Late Presentation

Despite the aforementioned efforts to encourage earlier and more frequent HIV testing and targeting at-risk populations, late presentation (presentation with low CD4 count) is unfortunately not a rarity. A consensus definition has been agreed in order to identify the extent to which it occurs [38, 39]. A common definition of late presentation is important. The term “late” indeed is central, as guidelines across the continent agree that ART should be started before the CD4 count drops below the threshold of 350 cells/mm³. Conversely, “late” may not necessarily imply that the person has been infected for several years, since data from seroconverter cohorts suggest that for around 20 % of people, the CD4 count is below 350 cells/mm³ by one year from infection [40]. Among adult HIV diagnoses in the EU/EEA (European Union and European Economic Area) region reported to ECDC (56 % completeness in 2011), 49 % were reported as late presentations (CD4 count at diagnosis <350 cells/mm³) and 29 % were reported as advanced HIV disease (CD4 count at diagnosis <200 cells/mm³) [8]. A large cohort collaboration study found that late presentation in Europe has declined from 57.3 % in 2000 to 51.7 % in 2010/2011; however late presentation was found to be most prevalent in heterosexual males, Southern European countries (Greece, Israel, Italy, Portugal and Spain), and people originating from Africa, suggesting key populations and regions for priority interventions [41••].

Access and Retention in Care

Retention in care includes both linkage to care following a diagnosis and subsequent retention in care. In particular, a clear and established pathway for onward referral for patients who test HIV-positive is intrinsic to achieve good rates of integration into HIV care services for timely ART initiation and attaining viral suppression. Many of the barriers that limit access to and retention in care elsewhere have been reduced and even removed in healthcare systems in Western Europe. Care is generally free and focuses not only to treat HIV infection but also co-infections and co-morbidities, including addiction and psychiatric diseases [42]. There are a minority of settings of concern that do not provide universal access to HIV prevention, treatment and care. The recent change in legislation in Spain preventing illegal immigrants from accessing HIV care is one notable example [43]. However, most people on ART in centres across Western Europe experience continued complete viral control. The level of viral load is the main predictor of HIV transmission risk [44]. Therefore the higher the proportion of people with suppressed viral load, the less chance of transmission of both drug-susceptible and drug-resistant strains. Perhaps largely due to on-going high rates of suppression in Europe, prevalence of transmitted drug resistance has been maintained below 10 % [45].
As life expectancies have improved over time in people living with HIV, we are now used to seeing a situation in Western Europe where a large group of people seen in care are over the age of 50 [46, 47]. The proportion of newly diagnosed cases of HIV in people aged 50 and above has also been gradually increasing each year, up from 11.9% in 2006 to 16.6% in 2012 [6]. It will therefore be important to ensure that HIV care services are adapted so that the needs of older people living with HIV are met. A more integrated approach to managing care may be appropriate, which would involve working closer with primary care physicians to manage HIV-related conditions but also non-HIV-related conditions which occur more frequently with older age.

**Men Who Have Sex with Men (MSM)**

Prevalence and Incidence

HIV infection has had a large impact on MSM in Western Europe and it still remains the predominant mode of HIV transmission. Reported prevalence is high, ranging from 0.5 to 17.7% [49]. The highest prevalences were found in France (17.7%), Spain (13.1%), Greece (12.7%) and Germany (11.5%). It is important to note here that these data were from various sources, mainly prevalence surveys, conducted in each country separately and may differ greatly by risk group definition, definition of a man who has sex with men, representativeness of the sample and sample size.

The UK, France, Netherlands, Germany, Denmark and Spain are examples of countries that have seen a gradual rise in the number of HIV diagnoses reported among MSM [8]. Studies published in the last few years have indicated that these rises are not just a result of higher testing rates and better surveillance systems, but are a result of an increase in transmission by condom-less sex [14, 50–52, 53•]. In many of these new infections, the probable source is thought to be HIV-positive people who are not yet diagnosed. These observations have been seen despite high ART coverage in people with CD4 count <350 cells/mm³ [54].

Risk Behaviour

Results from the European MSM Internet Survey (EMIS) found that men known to be HIV-positive were 2.4-fold more likely to report condom-less sex with a partner of discordant or unknown status (CLS-D) than HIV-negative and untested men [55]. The proportion of men who had CLS-D with any male partner in the preceding 12 months ranged from 25 to 41%. The study also found that countries in the Central-West and West regions had the lowest levels of CLS-D whereas countries in the South-East regions had the highest levels. Similarly, condom-use at last anal intercourse with a male partner also ranged from 28 to 76% over 35 countries in Europe, although around half the countries reported proportions between 40 and 60% [49]. Despite the limitations of the uncertain representativeness of those sampled, and the potential for social desirability bias in reporting, these data seem to indicate that sexual risk behaviour among MSM varies considerably from country to country.

**Heterosexual Transmission**

Migration from Countries with Generalised HIV Epidemics

Migrants from countries with generalised HIV epidemics, mainly from sub-Saharan Africa, represent a large proportion of heterosexually-acquired HIV and AIDS case reports in Western Europe. Although there are large disparities due to former colonial links, healthcare systems and social structures, the general trend is such that countries with large migrant populations in the general population will have large numbers of migrants among those presenting with HIV [56]. The reported number of cases of HIV diagnoses in Western Europe originating from sub-Saharan Africa has nearly halved in the years between 2006 and 2012 (Fig. 1) [6]. In contrast, for example in the UK, there has been a rise in the proportion of diagnoses among people born abroad but who probably acquired their infection in the UK [57].

Of individuals infected through heterosexual contact and diagnosed in 2011, the proportion of reported cases in people originating from a country with a generalised epidemic varied from 5.6% in Finland to 66.4% in Ireland, which are much higher than levels seen in Central and Eastern European countries [6]. A major concern is that more than 60% of migrants from generalised epidemic countries are considered to be late presenters [58] and many probably have a CD4 count below 350 cells/mm³ before arrival in Europe. As mentioned earlier, although many countries recognise that migrants and ethnic minorities are particularly vulnerable to HIV [59], testing and care are not universally available in all settings, particularly for those with uncertain or illegal migrant status.

Migration from East to West

The effect of migration from Eastern to Western Europe is unclear, but absolute numbers of European migrants diagnosed with HIV are small to date [56]. The exceptions are for countries with close borders to countries in the Eastern Europe and Central Asia region where the epidemic has around the turn of the millennium been mainly driven by injecting drug use, but more recently mixed with heterosexual and some MSM transmission [60, 61].
Injecting Drug Use

Importance of Harm-Reduction Services

Across Western Europe, there have been low rates of new infections among PWID due to the wide implementation and success of harm-reduction policies and services [6]. Where data are available, it seems that all countries in Western Europe provide needle and syringe exchange programmes, opioid substitution treatment (OST) and ART for PWID, which is much higher than the average global coverage [62].

However, a number of European countries reported a rise in the number of new HIV diagnoses among PWID in 2011, most notably Greece and Romania [63]. Both countries reported a ten-fold rise; in Greece, the number of HIV diagnoses increased from 22 cases in 2010 to 245 cases in 2011 and similarly in Romania, from nine cases in 2010 to 108 cases in 2011 [8]. Greece attributes the outbreak to the shortage of needle and syringe exchange programmes and long waiting times for access to OST prior to 2011 [64]. In Romania, evidence from behavioural surveillance surveys conducted in PWID suggested changes in drug-use patterns (amphetamine-type stimulants, associated with more frequent injections and increased sharing of injecting equipment, became more common than heroin) [64]. However similarly to the situation in Greece, access to harm reduction services also declined alongside due to the withdrawal of international programs and funding support [63, 64]. These recent outbreaks of HIV transmission among PWID serve as a reminder that these policies are fragile and vulnerable in countries affected by economic constraints, and stress the need for continuing public health and preventative services.

Co-Infection with Hepatitis C

PWID are at the highest risk of being co-infected with hepatitis C virus (HCV). Of patients in a Europe-wide cohort 78% who were HCV-positive had acquired HIV-1 via injecting drug use and most likely acquired HCV through this route too [65]. For people with HCV, co-infection with HIV is known to be strongly associated with poorer prognosis with an increased risk of developing liver disease and HCV-related mortality [66]. Expanded access to HCV diagnosis and treatment will therefore be important in conjunction with harm-reduction and HIV-related programs to control the evolving epidemic.

Mother-to-Child Transmission (MTCT)

The probability of a child with an HIV-positive mother being born with HIV have now reduced to approximately 1 to 2% in Western Europe, due to effective preventative interventions including universal antenatal testing, caesarean sections, formula feeding and particularly through use of ART [67, 68]. However over the last decade, it has been shown that 40% of MTCT are due to insufficient antenatal ART for the women, even though half of them were diagnosed pre-conception [69]. It appears that there remain missed opportunities for prevention of MTCT which may be improved by better engagement and retention in care and by providing support for women before, during and after pregnancy, to achieve and sustain viral suppression [69, 70].

Social Inequalities

The HIV epidemic in Western Europe is concentrated in MSM and PWID, but also disproportionately affects other marginalised populations including migrants, sex workers, transgender people and prisoners. HIV-related stigma and discrimination are commonly faced by these populations, acting as a major barrier to the integral care and support that is needed. These barriers can hinder the success of interventions and programmes to provide access to prevention schemes, HIV testing, linkage to and retention in care, and use of ART [35, 71–73]. We highlight the recent events in Greece as a regretful example, where police detained, tested and then publicised people’s HIV status [74]. These actions, as a consequence of the change in law, have and will continue to damage and undo all the benefits which have taken place so far to combat the epidemic.

The Euro HIV index 2009 was a study conducted to assess the quality of HIV policies and services and the social inequalities present in 29 European countries. The study authors concluded that the countries rated as having the best HIV care were Luxembourg, Malta, Switzerland, Finland and the Netherlands [75]. These countries were the ones with the most effective prevention programmes and good access to care, especially for people who are part of marginalised populations. Societal inequalities existed in varying degrees among the countries surveyed, but the notable areas requiring improvements were the stigma and discrimination faced by vulnerable and marginalised populations and lack of universal access to HIV testing, care and treatment.

Conclusions

Although in Western Europe the absolute number of people affected by HIV is relatively small compared to other areas such as sub-Saharan Africa and Eastern Europe, it is still a significant public health issue. Fortunately, many countries within this region are resource-rich and have been equipped with solid infrastructures and good quality healthcare systems. Consequently, Western Europe leads globally in terms of the accessibility and standard of HIV care, but even within this
region, large differences are seen, as found in the Euro HIV Index 2009. One issue that the study highlighted was the lack of good epidemiological data. Understanding the individual country epidemics, by means of collecting good quality surveillance data, is crucial to be able to provide the appropriate services and programs that are needed in these settings [76•]. Estimation of the number of people living with HIV and the size of the undiagnosed proportion would therefore be very informative for people working in public health and policy makers.

With no evidence of a decline in HIV incidence in Western Europe, it will be important to plan for and provide the appropriate HIV services for years to come. A major challenge which is faced by many countries already is taking care of the ageing population, including people newly diagnosed but also those who have lived with HIV for decades and are now reaching ages where the risk of comorbidities are much greater. Lastly, there is still a vital need to address the barriers which exist that prevent universal access to HIV prevention services, treatment and care.

Compliance with Ethics Guidelines

Conflict of Interest  Fumiyo Nakagawa, Andrew N. Phillips, and Jens D. Lundgren declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent  This article does not contain any studies with human or animal subjects performed by any of the authors.

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

Papers of particular interest, published recently, have been highlighted as:

- Of importance
- Of major importance

1. Joint United Nations Programme on HIV/AIDS (UNAIDS). Global report: UNAIDS report on the global AIDS epidemic 2013. 2013.
2. Stover J. Projecting the demographic consequences of adult HIV prevalence trends: the Spectrum Projection Package. Sex Transm Infect. 2004;80 Suppl 1:i4–8.
3. Stover J, Brown T, Marston M. Updates to the Spectrum/Estimiation and Projection Package (EPP) model to estimate HIV trends for adults and children. Sex Transm Infect. 2012;88 Suppl 2:i11–6.
4. Nakagawa F, May M, Phillips A. Life expectancy living with HIV: recent estimates and future implications. Curr Opin Infect Dis. 2013;26(1):17–25.
5. Orbland KE, Lozano R, Murray CJL. The burden of HIV: insights from the Global Burden of Disease Study 2010. AIDS. 2013;27(13):2003–17. A global study which evaluated by country, the burden of HIV infection in terms of disability adjusted life years (DALYs) between 1980 and 2010.
6. European Centre for Disease Prevention and Control/WHO Regional Office for Europe. HIV/AIDS Surveillance in Europe 2012. Stockholm: European Centre for Disease Prevention and Control; 2013.
7. UNAIDS/WHO Working Group on Global HIV/AIDS and STI Surveillance. Surveillance of the HIV/AIDS epidemic: a comprehensive package. October 2013. Geneva, Switzerland. http://www.who.int/hiv/pub/surveillance/2013package/en/index.html. 2013.
8. European Centre for Disease Prevention and Control/WHO Regional Office for Europe. HIV/AIDS surveillance in Europe 2011. Stockholm: European Centre for Disease Prevention and Control; 2012.
9. Herida M, Alix J, Devaux I, Likatavicius G, Desenclos JC, Matic S, et al. HIV/AIDS in Europe: epidemiological situation in 2006 and a new framework for surveillance. Euro Surveill 2007;12(47).
10. Sonnenberg P, Clifton S, Beddows S, Field N, Soldan K, Tanton C, et al. Prevalence, risk factors, and uptake of interventions for sexually transmitted infections in Britain findings from the National Surveys of Sexual Attitudes and Lifestyles (Natals). Lancet. 2013;382(9907):1795–806.
11. Vanden Berghe W, Nöstlinger C, Buve A, Beelaert G, Franssen K, Laga M. A venue-based HIV prevalence and behavioural study among men who have sex with men in Antwerp and Ghent, Flanders, Belgium, October 2009 to March 2010. Euro Surveill 2011;16(28).
12. Barin F, Nardone A. Monitoring HIV epidemiology using assays for recent infection: where are we? Euro Surveill 2008;13(36).
13. Garrett N, Lattimore S, Gilchrist V, Aghaizou A, Mensah G, Tosswell J, et al. The Recent Infection Testing Algorithm (RITA) in clinical practice: a survey of HIV clinicians in England and Northern Ireland. HIV Med. 2012;13(7):444–7. Algorithms to estimate how recent the HIV infection occurred are increasingly used to estimate HIV incidence and to improve the understanding of transmission dynamics in concentrated epidemics. This study showed that informing patients of RITA results did not lead to adverse events.
14. Semaille C, Cazenev F, Lot F, Pillonel J, Le Vu S, Le Strat Y, et al. Recently acquired HIV infection in men who have sex with men (MSM) in France, 2003-2008. Euro Surveill. 2009;14(14):E5–8.
15. Vereauteren J, Wensing AMJ, van de Vijver DAMC, Albert J, Balotta C, Hamouda O, et al. Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis. 2009;200(10):1503–8.
16. Hamers FF, Phillips AN. Diagnosed and undiagnosed HIV-infected populations in Europe. HIV Med. 2008;9:6–12.
17. Eldred L, Malitz F. Introduction [to the supplemental issue on the HRSA SPNS Outreach Initiative]. AIDS Patient Care STDS. 2007;21 Suppl 1:S1–2.
18. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.
19. Loufty MR, Wu W, Letchumanan M, Bondy L, Antoniou T, Margoese S, et al. Systematic review of HIV transmission between heterosexual serodiscordant couples where the HIV-positive partner is fully suppressed on antiretroviral therapy. PLoS One. 2013;8(2):e55747.
20. Delpech V, Brown A, Conti S, Polavarapu V, Yin Z. Reducing onward transmission: Viral suppression among key population groups living with HIV in the United Kingdom. 19th Annual Conference of the British HIV Association (BHHV). Manchester, UK. Abstract# O18. 2013.
21. Supervie V, Costagliola D. The spectrum of engagement in HIV care in France: strengths and gaps. 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, USA: March 2013. Abstract#1030. 2013.
Antinori A, Coenen T, Costagiola D, Dedes N, Ellefson M, Gatell J, Yazdanpanah Y, Lange J, Gerstoft J, Cairns G. Earlier testing for HIV in persons living with HIV who are aware and unaware of their infection. AIDS. 2012;26(7):893–6.

Brown A, Gill O, Delpech V. HIV treatment as prevention among men who have sex with men in the UK: is transmission controlled by universal access to HIV treatment and care? HIV Med. 2013;14(9):563–70.

Raben D, Delpech V, De WJ, Sullivan A, Lazarus J, Dedes N, et al. Conclusions from the HIV in Europe Copenhagen 2012 Conference and ways forward: working together for optimal HIV testing and earlier care. HIV Med. 2013;14 Suppl 3:1–5.

Gazzard B, Clumeneck N, Monforte A, Lundgren J. Indicator disease-guided testing for HIV - the next step for Europe? HIV Med. 2008;9:34–40.

Sullivan AK, Raben D, Reekie J, Raymond M, Mocroft A, Esser S, et al. Feasibility and effectiveness of indicator condition-guided testing for HIV: results from HIDES I (HIV indicator diseases across Europe study). PLoS One. 2013;8(1):e52845. Results from a study investigating a method to improve targeted HIV testing. The authors found that testing people presenting with one of eight indicator conditions/diseases to any healthcare setting was cost-effective and should be encouraged.

Mounier-Jack S, Nielsen S, Coker RJ. HIV testing strategies across European countries. HIV Med. 2008;9:13–9.

European Centre for Disease Prevention and Control. HIV testing: increasing uptake and effectiveness in the European Union. Stockholm: ECDC; 2010.

Rayment M, Rae C, Ghooloo F, Doku E, Hardie J, Finlay S, et al. Routine HIV testing in the emergency department: tough lessons in sustainability. HIV Med. 2013;14:6–9.

Bums F, Edwards S, Woods J, Haidari G, Calderon Y, Leider J, et al. Acceptability, feasibility and costs of universal offer of rapid point of care testing for HIV in an acute admissions unit: results of the RAPID project. HIV Med 2013; 14:10–14.

Meulbroek M, Ditzel E, Saz J, Taboada H, Perez F, Perez A, et al. BCN Checkpoint, a community-based centre for men who have sex with men in Barcelona, Catalonia, Spain, shows high efficiency in HIV detection and linkage to care. HIV Med. 2013;14:25–8.

Rayment M, Doku E, Thornton A, Pearn M, Sudhanva M, Jones R, et al. Automatic oral fluid-based HIV testing in screening programmes: automatic for the people. HIV Med. 2013;14:49–52.

Ng OT, Chow AL, Lee VJ, Chen MI, Win MK, Tan HH, et al. Accuracy and user-acceptability of HIV self-testing using an oral fluid-based HIV rapid test. PLoS One. 2012;7(9):e5168. The OraQuick ADVANCE Rapid HIV 1/2 Antibody Test had a specificity of 99.9% and sensitivity of 97.4% in 994 people using self-tests for oral fluid-based HIV testing. The OraQuick ADVANCE Rapid HIV 1/2 Antibody Test had a specificity of 99.9% and sensitivity of 97.4% in 994 people using self-tests for HIV-1.

Deblonde J, De Koker P, Hamers FF, Fontaine J, Luchters S, Temmerman M. Barriers to HIV testing in Europe: a systematic review. Eur J Publ Health. 2010;20(4):422–32.

Hamill M, Burgoine K, Farrell F, Hemelaaar J, Patel G, Welch DE, et al. Time to move towards opt-out testing for HIV in the UK. BMJ. 2007;334(7608):1352–4.

Yazdanpanah Y, Lange J, Gerstoft J, Caims G. Earlier testing for HIV - how do we prevent late presentation? Antivir Ther. 2010;15:17–24.

Adler A, Mounier-Jack S, Coker R. Late diagnosis of HIV in Europe: definitional and public health challenges. AIDS Care-Psychol Socio-Med Asp AIDS/HIV. 2009;21(3):284–93.

Antonini A, Coenen T, Costagiola D, Dedes N, Ellfeson M, Gatell J, et al. Late presentation of HIV infection: a consensus definition. HIV Med. 2011;12(1):61–4.
del Amo J, Likatavicius G, Pérez-Cachafeiro S, Hernando V, González C, Jarrín I, et al. The epidemiology of HIV and AIDS reports in migrants in the 27 European Union countries, Norway and Iceland: 1999-2006. Eur J Publ Health. 2011;21(5):620–6.

57. Aghaizu A, Brown AE, Nardone A, Gill ON, Delpech VC, contributors. HIV in the United Kingdom 2013 Report: data to end 2012. London: Public Health England; 2013.

58. European Centre for Disease Prevention and Control. Responses to HIV and migration in western industrialised countries: current challenges, promising practices, future directions. Stockholm: ECDC; 2013.

59. Alvarez-del Arco D, Monge S, Caro-Murillo AM, Ramírez-Rubio O, Azcoaga-Lorenzo A, Belza MJ, et al. HIV testing policies for migrants and ethnic minorities in EU/EFTA Member States. The European Journal of Public Health 2013

60. Hamers FF, Downs AM. HIV in central and eastern Europe. Lancet. 2003;361(9362):1035–44.

61. Beyrer C, Abdool Karim Q. The changing epidemiology of HIV in 2013. Curr Opin HIV AIDS. 2013;8(4):306–10.

62. Mathers BM, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick RP, et al. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet. 2010;375(9719):1014–28.

63. Pharris A, Wiessing L, Stetcu O, Hedrich D, Botescu A, Fotou A, et al. Human immunodeficiency virus in injecting drug users in Europe following a reported increase of cases in Greece and Romania, 2011. Euro Surveill. 2011;16(48):14–8. Report on the recent rapid increase in cases of HIV among people who inject drugs in Greece and Romania. The rise in incidence was observed following the financial crisis in 2008-9 which contributed to lower coverage of prevention services.

64. Joint EMCDDA and ECDC rapid risk assessment. HIV in injecting drug users in the EU/EEA, following a reported increase of cases in Greece and Romania. 2012.

65. Rockstroh JK, Mocroft A, Soriani V, Tural C, Losso MH, Horban A, et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis. 2005;192(6):992–1002.

66. Taylor LE, Swan T, Mayer KH. HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms. Clin Infect Dis. 2012;55 suppl 1:S33–42.

67. European Collaborative Study. The mother-to-child HIV transmission epidemic in Europe: evolving in the East and established in the West. AIDS. 2006;20(10):1419–27.

68. Townsend CL, Cortina-Borja M, Peckham CS, de Ruiter A, Lyall H, Tookey PA. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS. 2008;22(8):973–81.

69. Bailey H, Townsend C, Cortina-Borja M, Thorne C. Insufficient antiretroviral therapy in pregnancy: missed opportunities for prevention of mother-to-child transmission of HIV in Europe. Antivir Ther. 2011;16(6):895–903.

70. Chiappini E, Galli L, Giaquinto C, Ene L, Goetghebuer T, Judd A, et al. Use of combination neonatal prophylaxis for the prevention of mother-to-child transmission of HIV infection in European high-risk infants. AIDS. 2013;27(6):991–1000.

71. Lazarus JV, Juergens R, Weait M, Phillips A, Hows J, Gatell J, et al. Overcoming obstacles to late presentation for HIV infection in Europe. HIV Med. 2011;12(4):246–9.

72. Fakoya I, Reynolds R, Caswell G, Shiripinda I. Barriers to HIV testing for migrant black Africans in Western Europe. HIV Med. 2008;9:23–5.

73. Nachega JB, Morroni C, Zuniga JM, Sherer R, Beyrer C, Solomon S, et al. HIV-related stigma, isolation, discrimination, and serostatus disclosure: a global survey of 2035 HIV-infected adults. J Int Assoc Phys AIDS Care (JIAPAC). 2012;11(3):172–8.

74. Lancet T. HIV testing in Greece: repeating past mistakes. Lancet. 2013;382(9887):102.

75. Health Consumer Powerhouse. The Euro HIV Index 2009: a reality check of public policy and best practice in 29 countries. 2009.

76. Working Group on Estimation of HIV Prevalence in Europe. HIV in hiding: methods and data requirements for the estimation of the number of people living with undiagnosed HIV. AIDS. 2011;25(8):1017–23. A review of methods currently in use to estimate the size of the undiagnosed fraction in HIV-infected populations.